Gene delivery to Jurkat T cells using non-viral vectors associated with magnetic nanoparticles

2010 ◽  
Vol 1 (2/3/4) ◽  
pp. 202 ◽  
Author(s):  
Yolanda Sanchez Antequera ◽  
Olga M. Mykhaylyk ◽  
Stefan Thalhammer ◽  
Christian Plank
Keyword(s):  
T Cells ◽  
Magnetic Nanoparticles ◽  
Gene Delivery ◽  
Viral Vectors ◽  
Jurkat T Cells

scholarly journals Genaration and assessment of immunomagnetic nanoparticles capable of T-cell removal

2019 ◽  
Vol 3 (2) ◽  
pp. 74-81
Author(s):  
Kien-Quang Huynh ◽  
Thuan Van Tran ◽  
Thao-Suong Tran-Nguyen ◽  
Kieu-Hanh Thi Ta ◽  
Hieu Tran-Van
Keyword(s):  
T Cells ◽  
Magnetic Nanoparticles ◽  
Magnetic Beads ◽  
Specific Binding ◽  
Protein A ◽  
Allogeneic Transplantation ◽  
Jurkat T Cells ◽  
Hematopoietic Stem ◽  
Donor Tissue ◽  
Covalently Linked

Hematopoietic stem cells (HSCs) transplantation has been the potential treatment for hematopoietic disorder patients. However, once they were prescribed HSCs transplantation as the therapy, especially allogeneic transplantation, they would face Graft versus Host disease (GvHD), which causes by the presence of T cells in donor tissue. To deal with the risk of GvHD, removal T cells in donor tissue prior to transplant to recipient is extremely indispensable. Nowadays, MACS technique using immuno-magnetic nanoparticles in order to deplete T cells shows potential solution in the transplantation. In this study, we prepared immuno-magnetic nanoparticles for separation of Jurkat T cells from cell culture. Anti-Jurkat T antibodies were conjugated onto magnetic nanoparticles via recombinant protein A/G, an antibody’s Fc specific binding protein. The bonds between protein A/G and immuno-magnetic nanoparticles were covalently linked by amine groups on the surface of magnetic nanoparticles and the protein through 3-(2 pyridyldithio) propionic acid N hydroxysuccinimide ester (SPDP). Approximately 85 μg of protein A/G and 21 μg of antibody were bound to one mg of magnetic beads. The immuno-magnetic nanoparticles were capable of isolating up to 53.3% of Jurkat T cells from culture medium.

The role of cbl family of ubiquitin ligases in gastric cancer exosome-induced apoptosis of Jurkat T cells

2009 ◽  
pp. 1-8
Author(s):  
Jing-Lei Qu ◽  
Xiu-Juan Qu ◽  
Ming-Fang Zhao ◽  
Yue-E Teng ◽  
Ye Zhang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
T Cells ◽  
Ubiquitin Ligases ◽  
Jurkat T Cells ◽  
Induced Apoptosis

Polyplex: A Promising Gene Delivery System

2019 ◽  
Vol 12 (6) ◽  
pp. 4681-4686
Author(s):  
Rohan Aggarwal ◽  
Monika Targhotra ◽  
Bhumika Kumar ◽  
P.K Sahoo ◽  
Meenakshi K Chauhan
Keyword(s):  
Gene Transfer ◽  
Gene Delivery ◽  
Delivery System ◽  
Viral Vectors ◽  
Gene Delivery System ◽  
Cationic Polymers ◽  
Therapeutic Application ◽  
Promising Alternative ◽  
Structure And Stability ◽  
The Past

In the past few years gene delivery system has gained a huge attention owing to its proved efficacy in several diseases especially in those caused by genetic and/oroncological malfunctioning. The effective gene delivery mainly depends on the carrier molecules that can ensure the safe and specific delivery of the nucleic acidmolecules. Viral vectors have been used for a longer period as the gene transfer vehicle. However, these viral vectors have potential immunological disadvantages that made them less preferred. Recently, non-viral vectors such as polyplexes have emerged as a promising alternative for viral vectors. Polyplexes are formed by conjugating a polymer with DNA and in maximum cases the cationic polymers are preferred over others. The structure and stability of the polyplexes depends on various factors. The ability of the polymer to condense the DNA mainly dictates the efficiency of the polyplex mediated transfection. In this review we are going to provide a framework for the synthesis and design of the polyplexes along with the structure and stability of the complexes pertaining to mechanism of action, characterization and therapeutic application, including polyethyleneimine mediated cytotoxicity as well as newer strategies for the generation of better polyplexes.

Stepwise Development of Biomimetic Chimeric Peptides for Gene Delivery

2020 ◽  
Vol 27 (8) ◽  
pp. 698-710
Author(s):  
Roya Cheraghi ◽  
Mahboobeh Nazari ◽  
Mohsen Alipour ◽  
Saman Hosseinkhani
Keyword(s):  
Gene Delivery ◽  
Targeted Delivery ◽  
Viral Vectors ◽  
Large Scale ◽  
Transfection Efficiency ◽  
Cationic Lipids ◽  
Target Cells ◽  
Scale Production ◽  
Stepwise Development ◽  
Chimeric Peptides

Gene-based therapy largely relies on the vector type that allows a selective and efficient transfection into the target cells with maximum efficacy and minimal toxicity. Although, genes delivered utilizing modified viruses transfect efficiently and precisely, these vectors can cause severe immunological responses and are potentially carcinogenic. A promising method of overcoming this limitation is the use of non-viral vectors, including cationic lipids, polymers, dendrimers, and peptides, which offer potential routes for compacting DNA for targeted delivery. Although non-viral vectors exhibit reduced transfection efficiency compared to their viral counterpart, their superior biocompatibility, non-immunogenicity and potential for large-scale production make them increasingly attractive for modern therapy. There has been a great deal of interest in the development of biomimetic chimeric peptides. Biomimetic chimeric peptides contain different motifs for gene translocation into the nucleus of the desired cells. They have motifs for gene targeting into the desired cell, condense DNA into nanosize particles, translocate the gene into the nucleus and enhance the release of the particle into the cytoplasm. These carriers were developed in recent years. This review highlights the stepwise development of the biomimetic chimeric peptides currently being used in gene delivery.

Targeted adenovirus-mediated gene delivery to T cells via CD3.

1997 ◽  
Vol 71 (10) ◽  
pp. 7663-7669 ◽  
Author(s):  
T J Wickham ◽  
G M Lee ◽  
J A Titus ◽  
G Sconocchia ◽  
T Bakács ◽  
...  
Keyword(s):  
T Cells ◽  
Gene Delivery

scholarly journals Epicutaneous immunization with modified vaccinia Ankara viral vectors generates superior T cell immunity against a respiratory viral challenge

npj Vaccines ◽  
2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Youdong Pan ◽  
Luzheng Liu ◽  
Tian Tian ◽  
Jingxia Zhao ◽  
Chang Ook Park ◽  
...  
Keyword(s):  
T Cells ◽  
Viral Vectors ◽  
Effector T Cells ◽  
T Cell Immunity ◽  
Smallpox Vaccine ◽  
Respiratory Pathogens ◽  
Cell Immunity ◽  
Respiratory Challenge ◽  
Respiratory Droplets ◽  
Route Of Delivery

AbstractModified Vaccinia Ankara (MVA) was recently approved as a smallpox vaccine. Variola is transmitted by respiratory droplets and MVA immunization by skin scarification (s.s.) protected mice far more effectively against lethal respiratory challenge with vaccinia virus (VACV) than any other route of delivery, and at lower doses. Comparisons of s.s. with intradermal, subcutaneous, or intramuscular routes showed that MVAOVA s.s.-generated T cells were both more abundant and transcriptionally unique. MVAOVA s.s. produced greater numbers of lung Ova-specific CD8+ TRM and was superior in protecting mice against lethal VACVOVA respiratory challenge. Nearly as many lung TRM were generated with MVAOVA s.s. immunization compared to intra-tracheal immunization with MVAOVA and both routes vaccination protected mice against lethal pulmonary challenge with VACVOVA. Strikingly, MVAOVA s.s.-generated effector T cells exhibited overlapping gene transcriptional profiles to those generated via intra-tracheal immunization. Overall, our data suggest that heterologous MVA vectors immunized via s.s. are uniquely well-suited as vaccine vectors for respiratory pathogens, which may be relevant to COVID-19. In addition, MVA delivered via s.s. could represent a more effective dose-sparing smallpox vaccine.

Sign in / Sign up

Export Citation Format

Share Document